Reversible induction of ATP synthesis by DNA damage and repair in Escherichia coli. In vivo NMR studies.
Early metabolic events in Escherichia coli exposed to nalidixic acid, a topoisomerase II inhibitor and an inducer of the SOS system, were investigated by in vivo NMR spectroscopy, a technique that permits monitoring of bacteria under controlled physiological conditions. The energetics of AB1157 (wild type) and of its isogenic, SOS-defective mutants, recBC, lexA, and DeltarecA, were studied by 31P and 19F NMR before, during, and after exposure to nalidixic acid. The content of the NTP in E. coli embedded in agarose beads and perfused at 36 degreesC was found to be 4.3 +/- 1.1 x 10(-18) mol/cell, yielding a concentration of approximately 2.7 +/- 0.7 mM. Nalidixic acid induced in the wild type and mutants a rapid 2-fold increase in the content of the NTP, predominantly ATP. This induction did not involve synthesis of uracil derivatives or breakdown of RNA and caused cell proliferation to stop. Removal of nalidixic acid after 40 min of treatment rescued the cells and resulted in a decrease of ATP to control levels and resumption of proliferation. However, in DeltarecA cells, which were more sensitive to the activity of the drug, ATP elevation could not be reversed, and ATP content continued to increase faster than in control cells. The results ruled out association between the elevation of ATP and the induction of the SOS system and suggested involvement of a process reminiscent of apoptosis in the stimulation of ATP synthesis. Thus, the presence of the RecA protein was found to be essential for reversing the ATP increase and cell rescue, possibly by its function in repair of DNA damage.
Dahan-Grobgeld
E
E
Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.
Livneh
Z
Z
Maretzek
A F
AF
Polak-Charcon
S
S
Eichenbaum
Z
Z
Degani
H
H
D000255:Adenosine Triphosphate / Q000096:biosynthesis*; D000890:Anti-Infective Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000378:metabolism; D004249:DNA Damage; D004260:DNA Repair; D004269:DNA, Bacterial / Q000502:physiology*; D004926:Escherichia coli / Q000235:genetics* / Q000378:metabolism; D029968:Escherichia coli Proteins; D043211:Exodeoxyribonuclease V; D005090:Exodeoxyribonucleases / Q000378:metabolism; D005472:Fluorouracil / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D009268:Nalidixic Acid / Q000494:pharmacology; D013014:SOS Response, Genetics; D012697:Serine Endopeptidases / Q000378:metabolism; D000099160:LexA Repressor Protein
D000255:Adenosine Triphosphate; D000890:Anti-Infective Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D029968:Escherichia coli Proteins; D043211:Exodeoxyribonuclease V; D005090:Exodeoxyribonucleases; D005472:Fluorouracil; D009268:Nalidixic Acid; D012697:Serine Endopeptidases; D000099160:LexA Repressor Protein; C468322:exodeoxyribonuclease V, E coli